Published in Cancer Biol Ther on April 01, 2011
Construction of a tumor cell-targeting non-viral gene delivery vector with polyethylenimine modified with RGD sequence-containing peptide. Oncol Lett (2013) 0.77
Peptide-based technologies to alter adenoviral vector tropism: ways and means for systemic treatment of cancer. Viruses (2014) 0.77
Cell-Surface Integrins and CAR Are Both Essential for Adenovirus Type 5 Transduction of Canine Cells of Lymphocytic Origin. PLoS One (2017) 0.75
Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (1997) 14.41
Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell (1993) 13.21
CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol (1998) 6.83
Cytokine-induced proliferation and immunoglobulin production of human B lymphocytes triggered through their CD40 antigen. J Exp Med (1991) 3.04
Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest (2000) 2.70
Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol (1996) 2.52
Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J (1997) 2.43
Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery. J Virol (1995) 2.41
Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. J Virol (1996) 2.38
Methods for construction of adenovirus vectors. Mol Biotechnol (1995) 2.37
Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur J Cancer (2004) 1.60
Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther (2004) 1.51
Adenoviral-mediated gene transfer in lymphocytes. Proc Natl Acad Sci U S A (1998) 1.51
Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol (2000) 1.33
Genetically targeted adenovirus vector directed to CD40-expressing cells. J Virol (2003) 1.18
RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma. Gene Ther (2008) 1.05
Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge. J Virol (2003) 1.02
Adenovirus vector infection of chronic lymphocytic leukemia B cells. Blood (1996) 1.02
A novel canine lymphoma cell line: a translational and comparative model for lymphoma research. Leuk Res (2007) 1.01
Unexpected pulmonary uptake of adenovirus vectors in animals with chronic liver disease. Gene Ther (2004) 0.97
Intravenous administration of recombinant adenoviruses causes thrombocytopenia, anemia and erythroblastosis in rabbits. J Gene Med (2000) 0.92
Canine lymphoma-associated antigens defined by murine monoclonal antibodies. Cancer Immunol Immunother (1987) 0.89
Adenoviral gene therapy in gastric cancer: a review. World J Gastroenterol (2008) 0.89
Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein. Gene Ther (1999) 0.88
Adenovirus as a gene therapy vector for hematopoietic cells. Cancer Gene Ther (2000) 0.86
Enhancement of adenovirus vector entry into CD70-positive B-cell Lines by using a bispecific CD70-adenovirus fiber antibody. J Virol (2001) 0.85
Adenoviral vectors--how to use them in cancer gene therapy? Virus Res (2006) 0.84
Adenoviral gene therapy in head and neck cancer. Drug News Perspect (2006) 0.83
Efficient transduction of murine B lymphocytes and B lymphoma lines by modified adenoviral vectors: enhancement via targeting to FcR and heparan-containing proteins. Gene Ther (2001) 0.80
An allogeneic hybrid-cell fusion vaccine against canine mammary cancer. Vet Immunol Immunopathol (2008) 0.80
Phenotype-rescue of cyclin-dependent kinase inhibitor p16/INK4A defects in a spontaneous canine cell model of breast cancer. J Cell Biochem (2009) 0.80
hCAR-EGFP fusion receptor in human follicular lymphoma B cells - a model for adenoviral gene therapy for B cell malignancies. Int J Mol Med (2006) 0.77
Effects of recombinant adenovirus-mediated expression of IL-2 and IL-12 in human B lymphoma cells on co-cultured PBMC. Genet Vaccines Ther (2004) 0.77
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Corneal avascularity is due to soluble VEGF receptor-1. Nature (2006) 4.77
Engineering targeted viral vectors for gene therapy. Nat Rev Genet (2007) 3.69
Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther (2007) 2.56
A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol Ther (2008) 2.22
A national patient navigator training program. Health Promot Pract (2008) 2.17
Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24. Cancer Res (2010) 2.13
MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells. Cancer Biol Ther (2004) 1.90
Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther (2006) 1.88
Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst (2003) 1.86
A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther (2003) 1.86
Current issues and future directions of oncolytic adenoviruses. Mol Ther (2009) 1.80
Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res (2002) 1.74
Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res (2002) 1.74
Enhanced adenovirus infection of melanoma cells by fiber-modification: incorporation of RGD peptide or Ad5/3 chimerism. Cancer Biol Ther (2003) 1.66
Self-assembling nanoclusters in living systems: application for integrated photothermal nanodiagnostics and nanotherapy. Nanomedicine (2005) 1.66
Patient navigation improves cancer diagnostic resolution: an individually randomized clinical trial in an underserved population. Cancer Epidemiol Biomarkers Prev (2012) 1.65
mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. Cancer Biol Ther (2003) 1.63
In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst (2002) 1.61
Covalently linked Au nanoparticles to a viral vector: potential for combined photothermal and gene cancer therapy. Nano Lett (2006) 1.61
mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther (2006) 1.56
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res (2008) 1.55
OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells. Mol Pharmacol (2008) 1.52
Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther (2007) 1.48
Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Mol Cancer Ther (2008) 1.48
A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res (2004) 1.44
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther (2003) 1.43
Oncolytic adenoviruses - selective retargeting to tumor cells. Oncogene (2005) 1.43
Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat (2007) 1.41
Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs (2011) 1.39
Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J Virol (2002) 1.35
Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol (2002) 1.35
mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Int J Oncol (2007) 1.34
Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol (2002) 1.33
Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc Natl Acad Sci U S A (2011) 1.31
Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Cancer Res (2007) 1.31
Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res (2002) 1.30
mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine Growth Factor Rev (2010) 1.30
Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther (2002) 1.28
Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology (2003) 1.28
Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology (2004) 1.27
Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biol Ther (2009) 1.25
Resistant starch: promise for improving human health. Adv Nutr (2013) 1.24
PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. Cancer Res (2010) 1.23
Structure and uncoating of immature adenovirus. J Mol Biol (2009) 1.23
A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res (2010) 1.21
The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J Neurosurg (2006) 1.21
Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int J Cancer (2006) 1.19
Identification of sites in adenovirus hexon for foreign peptide incorporation. J Virol (2005) 1.19
Fluorescently labeled adenovirus with pIX-EGFP for vector detection. Mol Imaging (2004) 1.18
Current developments in adenovirus-based cancer gene therapy. Future Oncol (2006) 1.18
Mechanism by which Mcl-1 regulates cancer-specific apoptosis triggered by mda-7/IL-24, an IL-10-related cytokine. Cancer Res (2010) 1.18
Genetically targeted adenovirus vector directed to CD40-expressing cells. J Virol (2003) 1.18
MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors. Cancer Biol Ther (2008) 1.18
The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res (2002) 1.17
Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum Gene Ther (2002) 1.16
Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res (2002) 1.15
Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res (2006) 1.15
Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach. Mol Ther (2009) 1.14
Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res (2002) 1.14
Promotion of incisional wound repair by human mesenchymal stem cell transplantation. Exp Dermatol (2008) 1.14
Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res (2003) 1.14
Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res (2002) 1.13
Genetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein IX for functional display on the virion. Mol Imaging (2006) 1.13
Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy. J Virol (2007) 1.13
Three-dimensional structure of canine adenovirus serotype 2 capsid. J Virol (2008) 1.13
Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther (2006) 1.12
Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Toxicol Appl Pharmacol (2006) 1.12
Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther (2004) 1.12
Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. Drug Resist Updat (2009) 1.12
Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling. Mol Cancer Ther (2008) 1.11
Primary renal neoplasia of dogs. J Vet Intern Med (2006) 1.11
Scavenger receptor A: a new route for adenovirus 5. Mol Pharm (2009) 1.10
A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer. Gynecol Oncol (2013) 1.10
Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95. Mol Cancer Ther (2008) 1.10
A novel class of vascular endothelial growth factor-responsive genes that require forkhead activity for expression. J Biol Chem (2006) 1.10
Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling. J Natl Cancer Inst (2006) 1.10
Transductional targeting of adenoviral cancer gene therapy. Curr Gene Ther (2004) 1.10
Members of adenovirus species B utilize CD80 and CD86 as cellular attachment receptors. Virus Res (2006) 1.09
MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK-dependent mechanism. Mol Cancer Ther (2009) 1.08
Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2007) 1.08
Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Res (2007) 1.07
HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach. PLoS One (2010) 1.07
Localization of the N-terminus of minor coat protein IIIa in the adenovirus capsid. J Mol Biol (2008) 1.06
PERK-dependent regulation of MDA-7/IL-24-induced autophagy in primary human glioma cells. Autophagy (2008) 1.06
Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus in mice. Radiology (2002) 1.06
Cisplatin enhances protein kinase R-like endoplasmic reticulum kinase- and CD95-dependent melanoma differentiation-associated gene-7/interleukin-24-induced killing in ovarian carcinoma cells. Mol Pharmacol (2009) 1.06
Genetic targeting strategies for adenovirus. Mol Pharm (2005) 1.05
Effectiveness of a community health worker cardiovascular risk reduction program in public health and health care settings. Am J Public Health (2012) 1.05
Surgery alone or in combination with radiation therapy for treatment of intracranial meningiomas in dogs: 31 cases (1989-2002). J Am Vet Med Assoc (2002) 1.05
Age-matched comparison reveals early electrocardiography and echocardiography changes in dystrophin-deficient dogs. Neuromuscul Disord (2011) 1.04
Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. Mol Ther (2010) 1.04
Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. J Immunol (2002) 1.04
A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer. Clin Cancer Res (2012) 1.04
OSU-03012 enhances Ad.7-induced GBM cell killing via ER stress and autophagy and by decreasing expression of mitochondrial protective proteins. Cancer Biol Ther (2010) 1.03
Molecular consequences of the pathogenic mutation in feline GM1 gangliosidosis. Mol Genet Metab (2008) 1.03
Genetic incorporation of HSV-1 thymidine kinase into the adenovirus protein IX for functional display on the virion. Virology (2005) 1.03
Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. Virol J (2008) 1.03
An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism. Virology (2004) 1.02